Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.50 |
| ▸ | F10 | P00742 | 17/20 | 0.49 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3156028 | 0.94 | F10 (0.47) | IRAK4F10IRAK1SMN1; SMN2TDP1 | |
| Trifluoroacetic Acid SCHEMBL3151400 | 0.94 | F10 (0.48) | IRAK4F10 | |
| SCHEMBL8267448 | 0.94 | IRAK4 (0.55) | IRAK4F10IRAK1 | |
| Trifluoroacetic Acid SCHEMBL3166311 | 0.91 | F10 (0.47) | IRAK4F10IRAK1 | |
| SCHEMBL8265127 | 0.89 | F10 (0.51) | IRAK4F10IRAK1SMN1; SMN2TDP1 | |
| Trifluoroacetic Acid SCHEMBL5201128 | 0.88 | F10 (0.44) | IRAK4F10IRAK1 | |
| Trifluoroacetic Acid SCHEMBL3903764 | 0.88 | IRAK4 (0.49) | IRAK4F10IRAK1SMN1; SMN2TDP1 | |
| SCHEMBL8265838 | 0.88 | F10 (0.53) | IRAK4F10IRAK1 | |
| SCHEMBL3160888 | 0.87 | F10 (0.51) | IRAK4F10 | |
| Trifluoroacetic Acid SCHEMBL3165919 | 0.86 | F10 (0.50) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700628-B2 | Aromatic ether derivatives useful as thrombin inhibitors | ELI LILLY AND COMPANY (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1817287-B1 | AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS | LILLY CO ELI (US) | 2010-02-10 | — | — | EP | disclosed |
| US-20090227566-A1 | AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS | ELI LILLY AND COMPANY | 2009-09-10 | — | — | US | disclosed |
| EP-1817287-A1 | AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS | Eli Lilly and Company (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006057845-A1 | AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227566-A1 | AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS | TFPI, F2, F11 | IRAK4 2856/4885F10 15/4885IRAK1 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.